United States Food and Drug Administration perspectives on the update to the objective performance criteria for surgically implanted heart valve prostheses.

Wu, Changfu; Kurtzman, Steven B; Laschinger, John; Johnson, Terri; Aguel, Fernando

Wu, Changfu; Kurtzman, Steven B; Laschinger, John; Johnson, Terri; Aguel, Fernando.

Afiliação

Wu C; Division of Cardiovascular Devices, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD 20993. Electronic address: Changfu.Wu@fda.hhs.gov.
Kurtzman SB; Division of Cardiovascular Devices, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD 20993.
Laschinger J; Division of Cardiovascular Devices, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD 20993.
Johnson T; Division of Biostatistics, Office of Surveillance and Biometrics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD 20993.
Aguel F; Division of Cardiovascular Devices, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD 20993.

Ann Thorac Surg ; 98(5): 1890-1, 2014 Nov.

Article em En | MEDLINE | ID: mdl-25441824

Assuntos

Doenças das Valvas Cardíacas/cirurgia; Próteses Valvulares Cardíacas; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próteses Valvulares Cardíacas / Doenças das Valvas Cardíacas Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google